Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue ...
Asianet Newsable on MSN
Eli Lilly’s oral obesity drug passes maintenance test after Wegovy, Zepbound — Wall Street flags win for Viking Therapeutics
According to analyst H.C. Wainwright, the positive study result from Lilly materially de-risks Viking's (VKTX) oral VK2735 ...
H.C. Wainwright notes that this morning, Eli Lilly (LLY) announced positive topline results from the Phase 3 ATTAIN-MAINTAIN trial, which the firm ...
4d
Viking Therapeutics (VKTX): Rethinking Valuation After a Sharp Pullback and Strong Multi‑Year Run
Viking Therapeutics (VKTX) has been on a wild ride this year, with shares sliding over the past month even after a massive run in the past 3 years. So what is the market rethinking here? See our ...
Upstart biotech company Viking Therapeutics ( VKTX 3.98%) is a potential takeover candidate in 2026. That's not a reason to buy the stock in itself, but does highlight the potential value in its ...
Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the stocks that will double in 2026. Earlier on November 12, Canaccord ...
An investment strategist has outlined ten sub-$10 billion market-cap companies he believes are positioned to benefit heading ...
With all of this in mind, let's check out my top 10 stocks to buy for 2026. They offer you a balanced blend of ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best biotech stocks to buy according to Wall Street analysts. On ...
One of the best healthcare stocks to own today looks to be Viking Therapeutics. It's down 3% this year as investors dumped ...
In recent days, options scanners identified unusually large and mostly bullish options trades in Viking Therapeutics, pointing to elevated interest from major investors. This burst of complex options ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results